Curated News
By: NewsRamp Editorial Staff
June 03, 2025
Tenpoint Therapeutics Names Melissa Epperly CFO Ahead of Key Drug Launch
TLDR
- Tenpoint Therapeutics appoints Melissa Epperly as CFO to leverage her financial expertise for the U.S. launch of BRIMOCHOL PF, enhancing its market position.
- Melissa Epperly's role as CFO at Tenpoint Therapeutics involves overseeing financial strategy and capital markets activities for BRIMOCHOL PF's potential U.S. launch.
- Tenpoint Therapeutics' development of BRIMOCHOL PF aims to improve vision for the aging population, addressing presbyopia affecting two billion people globally.
- Melissa Epperly joins Tenpoint Therapeutics with a rich background in biopharmaceutical finance, ready to advance BRIMOCHOL PF towards commercial success.
Impact - Why it Matters
The appointment of Melissa Epperly as CFO of Tenpoint Therapeutics marks a pivotal moment for the company as it gears up for the potential U.S. launch of BRIMOCHOL PF, a groundbreaking treatment for presbyopia. With her proven track record in financial leadership and capital markets, Epperly is poised to drive Tenpoint's transition into a commercial-stage entity, bringing innovative treatments to millions suffering from vision impairments. This development is significant for investors, patients, and the broader biotech industry, highlighting the potential for transformative therapies in addressing age-related eye conditions.
Summary
Tenpoint Therapeutics, a clinical-stage biotechnology company, has announced the appointment of Melissa Epperly as its new Chief Financial Officer (CFO). Epperly, with over two decades of financial leadership in the biopharmaceutical industry, will oversee the company's financial strategy and operational finance functions. This move comes as Tenpoint prepares for the potential U.S. launch of BRIMOCHOL PF, its lead candidate for treating presbyopia, a condition affecting approximately two billion people globally. Epperly's extensive experience, including her role in leading Zentalis Pharmaceuticals through a successful IPO, positions her as a key player in Tenpoint's growth into a commercial-stage company.
Tenpoint Therapeutics is focused on developing innovative treatments for ophthalmic conditions such as presbyopia, cataracts, and geographic atrophy. The company has completed two large Phase 3 pivotal trials for BRIMOCHOL PF and has submitted an NDA to the US FDA. Backed by prominent investors, Tenpoint is on the brink of making a significant impact in the field of vision rejuvenation. For more information, visit tenpointtherapeutics.com.
Source Statement
This curated news summary relied on content disributed by citybiz. Read the original source here, Tenpoint Therapeutics Names Melissa Epperly CFO Ahead of Key Drug Launch
